NASDAQ:VERU Veru (VERU) Stock Price, News & Analysis $0.86 -0.05 (-5.47%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Veru Stock (NASDAQ:VERU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Veru alerts:Sign Up Key Stats Today's Range$0.85▼$0.9050-Day Range$0.75▼$0.9352-Week Range$0.36▼$1.92Volume623,805 shsAverage Volume1.73 million shsMarket Capitalization$126.55 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewVeru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Read More… [Urgent] Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Veru Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks38th Percentile Overall ScoreVERU MarketRank™: Veru scored higher than 38% of companies evaluated by MarketBeat, and ranked 772nd out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVeru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVeru has received no research coverage in the past 90 days.Read more about Veru's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Veru are expected to grow in the coming year, from ($0.30) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Veru's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.79% of the outstanding shares of Veru have been sold short.Short Interest Ratio / Days to CoverVeru has a short interest ratio ("days to cover") of 20.7, which indicates bearish sentiment.Change versus previous monthShort interest in Veru has recently increased by 2.80%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.79% of the outstanding shares of Veru have been sold short.Short Interest Ratio / Days to CoverVeru has a short interest ratio ("days to cover") of 20.7, which indicates bearish sentiment.Change versus previous monthShort interest in Veru has recently increased by 2.80%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.27 News SentimentVeru has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Veru this week, compared to 2 articles on an average week.Search Interest6 people have searched for VERU on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Veru insiders have not sold or bought any company stock.Percentage Held by Insiders14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Veru's insider trading history. Receive VERU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter. Email Address VERU Stock News HeadlinesContrasting Abliva AB (publ) (OTCMKTS:NEVPF) and Veru (NASDAQ:VERU)October 17 at 2:33 AM | americanbankingnews.comVeru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management CongressOctober 16 at 8:30 AM | globenewswire.comTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? To uncover the full story and learn how you can potentially profit from it...October 17, 2024 | Porter & Company (Ad)Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.October 12, 2024 | finance.yahoo.comWeight loss drugs have one big issue; These companies want to fix itOctober 12, 2024 | msn.comVeru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...October 10, 2024 | finance.yahoo.comNature’s Ozempic: Zmyra vs Traditional Weight Loss Methods – My Honest ReviewOctober 5, 2024 | msn.comCrystal Palace v Chelsea: Women’s Super League – liveSeptember 28, 2024 | msn.comSee More Headlines VERU Stock Analysis - Frequently Asked Questions How have VERU shares performed this year? Veru's stock was trading at $0.72 at the start of the year. Since then, VERU stock has increased by 20.1% and is now trading at $0.8645. View the best growth stocks for 2024 here. How were Veru's earnings last quarter? Veru Inc. (NASDAQ:VERU) issued its earnings results on Thursday, August, 8th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The business had revenue of $3.95 million for the quarter, compared to the consensus estimate of $3.50 million. Veru had a negative trailing twelve-month return on equity of 115.99% and a negative net margin of 376.38%. Who are Veru's major shareholders? Veru's top institutional investors include SG Americas Securities LLC (0.05%). Insiders that own company stock include Mitchell Shuster Steiner, Harry Fisch, K Gary Barnette and Mario Eisenberger. View institutional ownership trends. How do I buy shares of Veru? Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veru investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Ford Motor (F), Walt Disney (DIS) and Moderna (MRNA). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)12/13/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPersonal Products Current SymbolNASDAQ:VERU CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone(305) 509-6897Fax312-595-9122Employees189Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+362.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,150,000.00 Net Margins-376.38% Pretax Margin-259.52% Return on Equity-115.99% Return on Assets-66.94% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.16 Sales & Book Value Annual Sales$14.09 million Price / Sales8.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book3.93Miscellaneous Outstanding Shares146,384,000Free Float125,597,000Market Cap$126.55 million OptionableOptionable Beta-0.49 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:VERU) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veru Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veru With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.